Abstract: Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient.
Abstract: Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine receptors or of D1 or D5 dopamine receptor signal transduction pathways and increase D1 or D5 dopamine receptor expression. Pharmaceutical compositions comprising D1 or D5 dopamine receptor agonists, antibodies to D1 or D5 dopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using D1 or D5 dopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.
Type:
Grant
Filed:
November 18, 2002
Date of Patent:
June 27, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Russell James Sheldon
Abstract: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
Type:
Grant
Filed:
August 27, 2003
Date of Patent:
June 20, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Russell James Sheldon
Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
Type:
Grant
Filed:
December 11, 2002
Date of Patent:
August 30, 2005
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Wieslaw Adam Mazur
Abstract: Compounds according to the following Formula (I): are effective in treating conditions characterized by excess metalloprotease activity.
Type:
Grant
Filed:
September 18, 2002
Date of Patent:
February 8, 2005
Assignee:
The Procter & Gamble Company
Inventors:
Stanislaw Pikul, Katherine King Mieling, Kelly Michelle Solinsky, Biswanath De, Neil Gregory Almstead, Michael George Natchus, Glen Edward Mieling
Abstract: Screening methods for identifying compounds that regulate skeletal muscle atrophy or hypertrophy, regulate the activity or expression of the vasoactive intestinal peptide receptors (VPAC) or regulate expression of vasoactive intestinal peptide (VIP) or VIP analogs are provided. Methods for the prophylactic or therapeutic treatment of skeletal muscle atrophy utilizing VPAC as the target for intervention are described.
Type:
Grant
Filed:
October 23, 2000
Date of Patent:
June 15, 2004
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Russell James Sheldon
Abstract: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.
Type:
Grant
Filed:
March 6, 2001
Date of Patent:
December 30, 2003
Assignee:
The Procter & Gamble Company
Inventors:
Robert Joseph Isfort, Russell James Sheldon